Zobrazeno 1 - 10
of 74
pro vyhledávání: '"John, Litchfield"'
Autor:
Shuxi Qiao, Brianna LaViolette, Brianna LaCarubba Paulhus, Xiangping Li, John Litchfield, Zhenhong Li, John C. Stansfield, Richard L. Gieseck III, Bei B. Zhang, Danna M. Breen
Publikováno v:
JCSM Rapid Communications, Vol 6, Iss 2, Pp 122-133 (2023)
Abstract Background Inflammation is a hallmark of cachexia; however, effective anti‐inflammatory treatments have not yet been identified. Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a key signalling node linking interleukin‐1 recept
Externí odkaz:
https://doaj.org/article/e431d4d801b04a6dae39ebe825e67012
Autor:
Ryosuke Arakawa, Akihiro Takano, Sangram Nag, Zhisheng Jia, Nahid Amini, Kevin P. Maresca, Lei Zhang, Edmund J. Keliher, Christopher R. Butler, Justin R. Piro, Tarek A. Samad, Deborah Smith, Deane Nason, Steve O’Neil, Patrick Trapa, Kari R. Fonseca, John Litchfield, Timothy McCarthy, Richard E. Carson, Christer Halldin
Publikováno v:
EJNMMI Research, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Background Monoacylglycerol lipase (MAGL) is a key serine hydrolase which terminates endocannabinoid signaling and regulates arachidonic acid driven inflammatory responses within the central nervous system. To develop [11C]PF-06809247 into a
Externí odkaz:
https://doaj.org/article/0b2d2f0ac72047df80a3f5d00a8935c1
Autor:
Yan Weng, Kari R. Fonseca, Yi-an Bi, Sumathy Mathialagan, Keith Riccardi, Elaine Tseng, Andrew J. Bessire, Mathew A. Cerny, David A. Tess, A. David Rodrigues, Amit S. Kalgutkar, John Litchfield, Li Di, Manthena V. S. Varma
Publikováno v:
Drug Metabolism and Disposition. 50:1312-1321
Autor:
David A, Tess, Emi, Kimoto, Amanda, King-Ahmad, Manoli, Vourvahis, A David, Rodrigues, Arthur, Bergman, Ruolun, Qui, Veena, Somayaji, Yan, Weng, Kari R, Fonseca, John, Litchfield, Manthena V S, Varma
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:605-614
PF-06835919 is a first-in-class ketohexokinase inhibitor (KHKi), recently under development for the treatment of metabolic and fatty liver diseases, which inhibited organic anion transporting polypeptide (OATP)1B1 in vitro and presented drug-drug int
Autor:
Heather Eng, David A. Griffith, Emi Yamaguchi, Manthena V.S. Varma, David A. Tess, John Litchfield, Rachel E. Kosa, Yi-an Bi, Amit S. Kalgutkar, Sangwoo Ryu, Mark A. West
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 377:169-180
It is generally presumed that uptake transport mechanisms are of limited significance in hepatic clearance for lipophilic or high passive-permeability drugs. In this study, we evaluated the mechanistic role of the hepato-selective organic anion-trans
Autor:
Heather Eng, John Litchfield, David A. Griffith, Manthena V.S. Varma, David A. Tess, David J. Edmonds, Amit S. Kalgutkar
Publikováno v:
Journal of Medicinal Chemistry. 63:11831-11844
Prospective predictions of human hepatic clearance for anionic/zwitterionic compounds, which are oftentimes subjected to transporter-mediated uptake, are challenging in drug discovery. We evaluated the utility of preclinical species, rats and cynomol
Autor:
Jessica Ward, John Litchfield, Keith Riccardi, Carina Tan, Elnaz Menhaji-Klotz, Markus Boehm, Paula M. Loria, Kevin D. Hesp, Janice A. Brown
Publikováno v:
ACS Med Chem Lett
[Image: see text] The atypical chemokine receptor CXCR7 has been studied in various disease settings including immunological diseases and heart disease. Efforts to elucidate the role of CXCR7 have been limited by the lack of suitable chemical tools w
Autor:
Christopher Keefer, Tristan S. Maurer, David A. Tess, Heather Eng, Anthony Carlo, Zhenhong Li, John Litchfield
Publikováno v:
Journal of Medicinal Chemistry. 63:6489-6498
Drug precipitation in the nephrons of the kidney can cause drug-induced crystal nephropathy (DICN). To aid mitigation of this risk in early drug discovery, we developed a physiologically based in silico model to predict DICN in rats, dogs, and humans
Autor:
Akihiro Takano, Nahid Amini, Edmund J. Keliher, Christer Halldin, Lei Zhang, Richard E. Carson, Patrick Trapa, Sangram Nag, Ryosuke Arakawa, Deane M. Nason, Kevin P. Maresca, Zhisheng Jia, John Litchfield, Tarek A. Samad, Christopher Ryan Butler, Justin R. Piro, Timothy J. McCarthy, Deborah L. Smith, Steve O’Neil, Kari R. Fonseca
Background Monoacylglycerol lipase (MAGL) is a key serine hydrolase which terminates endocannabinoid signaling and regulates arachidonic acid driven inflammatory responses within the central nervous system. To develop [11C]PF-06809247 into a clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17b463c48140050426b0c96d37c2ff81
https://doi.org/10.21203/rs.3.rs-510615/v2
https://doi.org/10.21203/rs.3.rs-510615/v2
Autor:
Ryosuke, Arakawa, Akihiro, Takano, Sangram, Nag, Zhisheng, Jia, Nahid, Amini, Kevin P, Maresca, Lei, Zhang, Edmund J, Keliher, Christopher R, Butler, Justin R, Piro, Tarek A, Samad, Deborah, Smith, Deane, Nason, Steve, O'Neil, Patrick, Trapa, Kari R, Fonseca, John, Litchfield, Timothy, McCarthy, Richard E, Carson, Christer, Halldin
Publikováno v:
EJNMMI research. 12(1)
Monoacylglycerol lipase (MAGL) is a key serine hydrolase which terminates endocannabinoid signaling and regulates arachidonic acid driven inflammatory responses within the central nervous system. To develop [Seven cynomolgus monkeys were enrolled for